Integrating Mobile Text Messaging Pre-Exposure Prophylaxis Navigation Services Into a Home HIV and Sexually Transmitted Infection Self-Testing Program in the United States: Formative Work and Pilot Implementation Study.
JMIR Form Res.
2026 Apr 21;10:e83733. doi: 10.2196/83733. PubMed PMID:
42013381; PubMed Central PMCID:
PMC13099030.
Interest in Long-Acting PrEP by Methamphetamine Use Among Men Who Have Sex with Men in Four Western US Cities.
AIDS Behav.
2026 Feb 12;. doi: 10.1007/s10461-026-05034-4. [Epub ahead of print] PubMed PMID:
41678009; PubMed Central PMCID:
PMC13098542.
Implementation Barriers and Facilitators in a Pilot Long-Acting HIV Treatment Intervention for Trans Women Living with HIV in San Francisco.
AIDS Patient Care STDS.
2025 Jul;39(7):257-265. doi: 10.1089/apc.2024.0259. Epub 2025 Jun 6. PubMed PMID:
40474770.
High Retention and Adherence With Rapid Long-acting Injectable Preexposure Prophylaxis Implementation in an Urban Safety Net Clinic Population.
Clin Infect Dis.
2025 Jun 4;80(5):1139-1142. doi: 10.1093/cid/ciae531. PubMed PMID:
39484783; PubMed Central PMCID:
PMC12135906.
Developing a Novel Mobile App to Support HIV Testing and Pre-Exposure Prophylaxis Uptake Among Men Who Have Sex With Men: Formative and Technical Pilot Study.
JMIR Hum Factors.
2025 May 29;12:e62830. doi: 10.2196/62830. PubMed PMID:
40440084; PubMed Central PMCID:
PMC12163352.
CROI 2025: global epidemiology and prevention of HIV and other sexually transmitted diseases.
Top Antivir Med.
2025 May 21;33(2):508-535. Review. PubMed PMID:
40472386.
Interest in Long-Acting Preexposure Prophylaxis (PrEP) Among Men at Risk for Human Immunodeficiency Virus Who Use Methamphetamine Participating in a Daily, Oral PrEP Adherence Trial in San Francisco, California.
Open Forum Infect Dis.
2025 May;12(5):ofaf280. doi: 10.1093/ofid/ofaf280. eCollection 2025 May. PubMed PMID:
40406373; PubMed Central PMCID:
PMC12096071.
Pre-Exposure Prophylaxis Awareness and Demand Creation: Overlooked Populations and Opportunities to Move Forward.
J Acquir Immune Defic Syndr.
2025 Apr 15;98(5S):e170-e180. doi: 10.1097/QAI.0000000000003626. PubMed PMID:
40163069; PubMed Central PMCID:
PMC12256081.
Innovation in Providing Equitable Pre-exposure Prophylaxis Services in the United States: Expanding Access in Nontraditional Settings.
J Acquir Immune Defic Syndr.
2025 Apr 15;98(5S):e156-e169. doi: 10.1097/QAI.0000000000003610. PubMed PMID:
40163068; PubMed Central PMCID:
PMC12987501.
Language Justice in Implementation Science: Experiences Working With Latinxs to End the HIV Epidemic.
J Acquir Immune Defic Syndr.
2025 Apr 15;98(5S):e104-e110. doi: 10.1097/QAI.0000000000003630. PubMed PMID:
40163061; PubMed Central PMCID:
PMC12558689.
The Effects of MyChoices and LYNX Mobile Apps on HIV Testing and Pre-Exposure Prophylaxis Use by Young US Sexual Minority Men: Results From a National Randomized Controlled Trial.
JMIR Public Health Surveill.
2025 Feb 5;11:e63428. doi: 10.2196/63428. PubMed PMID:
39908084; PubMed Central PMCID:
PMC11840373.
Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
Clin Infect Dis.
2024 Nov 22;79(5):1197-1207. doi: 10.1093/cid/ciae143. PubMed PMID:
38484128; PubMed Central PMCID:
PMC7616831.
Acceptability of an automated directly observed therapy (DOT) application for PrEP adherence support among young men who have sex with men: a qualitative exploration.
AIDS Care.
2024 Nov;36(11):1704-1718. doi: 10.1080/09540121.2024.2397133. Epub 2024 Sep 2. PubMed PMID:
39222964; PubMed Central PMCID:
PMC11511627.
CROI 2024: Global Epidemiology and Prevention of HIV and Other Sexually Transmitted Diseases.
Top Antivir Med.
2024 Jul 17;32(3):447-482. PubMed PMID:
39142289; PubMed Central PMCID:
PMC11293602.
Estimating the potential value of MSM-focused evidence-based implementation interventions in three Ending the HIV Epidemic jurisdictions in the United States: a model-based analysis.
J Int AIDS Soc.
2024 Jul;27 Suppl 1(Suppl 1):e26265. doi: 10.1002/jia2.26265. PubMed PMID:
38965982; PubMed Central PMCID:
PMC11224592.
History of Rectal Product Use and Country of Residence Influence Preference for Rectal Microbicide Dosage Forms Among Young Sexual and Gender Minorities: A Multi-country Trial Comparing Placebo Douche, Suppository, and Insert Products.
AIDS Behav.
2024 Aug;28(8):2577-2589. doi: 10.1007/s10461-024-04360-9. Epub 2024 May 13. PubMed PMID:
38740628; PubMed Central PMCID:
PMC11480948.
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.
JAMA Netw Open.
2024 May 1;7(5):e2412835. doi: 10.1001/jamanetworkopen.2024.12835. PubMed PMID:
38780941; PubMed Central PMCID:
PMC11117088.
Adapting mHealth Interventions (PrEPmate and DOT Diary) to Support PrEP Retention in Care and Adherence Among English and Spanish-Speaking Men Who Have Sex With Men and Transgender Women in the United States: Formative Work and Pilot Randomized Trial.
JMIR Form Res.
2024 Mar 27;8:e54073. doi: 10.2196/54073. PubMed PMID:
38536232; PubMed Central PMCID:
PMC11007601.
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States.
J Int AIDS Soc.
2024 Mar;27(3):e26223. doi: 10.1002/jia2.26223. PubMed PMID:
38444118; PubMed Central PMCID:
PMC10935712.
A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN-035.
J Int AIDS Soc.
2024 Mar;27(3):e26219. doi: 10.1002/jia2.26219. PubMed PMID:
38494656; PubMed Central PMCID:
PMC10945032.
A latent trajectory analysis of young sexual and gender minorities' adherence to three rectal microbicide placebo formulations (MTN-035; a randomized crossover trial).
BMC Public Health.
2023 Dec 8;23(1):2464. doi: 10.1186/s12889-023-17368-y. PubMed PMID:
38066471; PubMed Central PMCID:
PMC10709877.
New USPSTF Guidelines for HIV Preexposure Prophylaxis: Will More Choices Lead to Greater Impact?.
JAMA.
2023 Aug 22;330(8):699-701. doi: 10.1001/jama.2023.11700. PubMed PMID:
37606684; PubMed Central PMCID:
PMC10586231.
CROI 2023: Epidemiologic Trends and Prevention for HIV and Other Sexually Transmitted Infections.
Top Antivir Med.
2023 May;31(3):468-492. PubMed PMID:
37315512; PubMed Central PMCID:
PMC10266866.
A randomized trial of safety, acceptability and adherence of three rectal microbicide placebo formulations among young sexual and gender minorities who engage in receptive anal intercourse (MTN-035).
PLoS One.
2023;18(4):e0284339. doi: 10.1371/journal.pone.0284339. eCollection 2023. PubMed PMID:
37043527; PubMed Central PMCID:
PMC10096248.
Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083.
Lancet Reg Health Am.
2023 Feb;18:100416. doi: 10.1016/j.lana.2022.100416. eCollection 2023 Feb. PubMed PMID:
36844011; PubMed Central PMCID:
PMC9950652.
Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with Men.
AIDS Behav.
2023 Feb;27(2):719-732. doi: 10.1007/s10461-022-03805-3. Epub 2022 Aug 19. PubMed PMID:
35984607; PubMed Central PMCID:
PMC9908647.
The effect of an HIV preexposure prophylaxis panel management strategy to increase preexposure prophylaxis prescriptions.
AIDS.
2022 Nov 1;36(13):1783-1789. doi: 10.1097/QAD.0000000000003283. Epub 2022 Jun 22. PubMed PMID:
35730363; PubMed Central PMCID:
PMC9529898.
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).
AIDS Behav.
2022 Dec;26(12):4107-4114. doi: 10.1007/s10461-022-03736-z. Epub 2022 Jun 10. PubMed PMID:
35687192; PubMed Central PMCID:
PMC10265494.
CROI 2022: epidemiologic trends and prevention for HIV and SARS-CoV-2.
Top Antivir Med.
2022 Apr-May;30(2):426-453. PubMed PMID:
36346701; PubMed Central PMCID:
PMC9306688.
Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring.
PLoS One.
2022;17(2):e0263664. doi: 10.1371/journal.pone.0263664. eCollection 2022. PubMed PMID:
35192655; PubMed Central PMCID:
PMC8863232.
Users' Preferred Characteristics of Vaginal Rings for HIV Prevention: A Qualitative Analysis of Two Phase I Trials.
AIDS Res Hum Retroviruses.
2022 Apr;38(4):313-326. doi: 10.1089/AID.2021.0077. Epub 2022 Feb 11. PubMed PMID:
34969254; PubMed Central PMCID:
PMC9048173.
Feasibility and Acceptability of Home-Collected Samples for Human Immunodeficiency Virus Preexposure Prophylaxis and Severe Acute Respiratory Syndrome Coronavirus 2 Laboratory Tests in San Francisco Primary Care Clinics.
Open Forum Infect Dis.
2022 Feb;9(2):ofab657. doi: 10.1093/ofid/ofab657. eCollection 2022 Feb. PubMed PMID:
35087913; PubMed Central PMCID:
PMC8789566.
Expanding the Pie-Differentiated PrEP Delivery Models to Improve PrEP Uptake in the San Francisco Bay Area.
J Acquir Immune Defic Syndr.
2021 Dec 15;88(S1):S39-S48. doi: 10.1097/QAI.0000000000002809. PubMed PMID:
34757991; PubMed Central PMCID:
PMC8579985.
Population Impact and Efficiency of Improvements to HIV PrEP Under Conditions of High ART Coverage Among San Francisco Men Who Have Sex With Men.
J Acquir Immune Defic Syndr.
2021 Dec 1;88(4):340-347. doi: 10.1097/QAI.0000000000002781. PubMed PMID:
34354011; PubMed Central PMCID:
PMC8556308.
Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial.
J Womens Health (Larchmt).
2022 Jul;31(7):1029-1039. doi: 10.1089/jwh.2021.0121. Epub 2021 Oct 19. PubMed PMID:
34665672; PubMed Central PMCID:
PMC9299526.
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
N Engl J Med.
2021 Aug 12;385(7):595-608. doi: 10.1056/NEJMoa2101016. PubMed PMID:
34379922; PubMed Central PMCID:
PMC8448593.
Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States.
J Int AIDS Soc.
2021 Jun;24(6):e25747. doi: 10.1002/jia2.25747. PubMed PMID:
34118115; PubMed Central PMCID:
PMC8196716.
HIV self-testing and STI self-collection via mobile apps: experiences from two pilot randomized controlled trials of young men who have sex with men.
Mhealth.
2021;7:26. doi: 10.21037/mhealth-20-70. eCollection 2021. PubMed PMID:
33898595; PubMed Central PMCID:
PMC8063023.
Adapting technology-based HIV prevention and care interventions for youth: lessons learned across five U.S. Adolescent Trials Network studies.
Mhealth.
2021;7:21. doi: 10.21037/mhealth-20-43. eCollection 2021. PubMed PMID:
33898590; PubMed Central PMCID:
PMC8063021.
CROI 2021: Epidemiologic Trends in the HIV and SARS-CoV-2 Pandemics and HIV Prevention Research.
Top Antivir Med.
2021 Apr-May;29(2):309-327. Review. PubMed PMID:
34107201; PubMed Central PMCID:
PMC8224247.
The potential effect of COVID-19-related disruptions on HIV incidence and HIV-related mortality among men who have sex with men in the USA: a modelling study.
Lancet HIV.
2021 Apr;8(4):e206-e215. doi: 10.1016/S2352-3018(21)00022-9. Epub 2021 Feb 19. PubMed PMID:
33617783; PubMed Central PMCID:
PMC8045548.
The case for prescribing PrEP in community mental health settings.
Lancet HIV.
2021 Apr;8(4):e237-e244. doi: 10.1016/S2352-3018(20)30273-3. Epub 2021 Jan 22. PubMed PMID:
33493438.
Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study.
ACS Pharmacol Transl Sci.
2021 Feb 12;4(1):226-239. doi: 10.1021/acsptsci.0c00181. eCollection 2021 Feb 12. PubMed PMID:
33615175; PubMed Central PMCID:
PMC7888308.
Assessing the use of surveillance data to estimate the impact of prevention interventions on HIV incidence in cluster-randomized controlled trials.
Epidemics.
2020 Dec;33:100423. doi: 10.1016/j.epidem.2020.100423. Epub 2020 Nov 20. PubMed PMID:
33285419; PubMed Central PMCID:
PMC7938213.
"You can't have a PrEP program without a PrEP Coordinator": Implementation of a PrEP panel management intervention.
PLoS One.
2020;15(10):e0240745. doi: 10.1371/journal.pone.0240745. eCollection 2020. PubMed PMID:
33064763; PubMed Central PMCID:
PMC7567425.
DOT Diary: Developing a Novel Mobile App Using Artificial Intelligence and an Electronic Sexual Diary to Measure and Support PrEP Adherence Among Young Men Who Have Sex with Men.
AIDS Behav.
2021 Apr;25(4):1001-1012. doi: 10.1007/s10461-020-03054-2. Epub 2020 Oct 12. PubMed PMID:
33044687; PubMed Central PMCID:
PMC7979437.
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
AIDS Behav.
2020 Sep;24(9):2520-2531. doi: 10.1007/s10461-020-02808-2. PubMed PMID:
32052214; PubMed Central PMCID:
PMC7423859.
Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV.
Front Pharmacol.
2020;11:1288. doi: 10.3389/fphar.2020.01288. eCollection 2020. PubMed PMID:
32982729; PubMed Central PMCID:
PMC7479819.
The importance of PrEP persistence in preventing HIV infections on PrEP.
J Int AIDS Soc.
2020 Aug;23(8):e25578. doi: 10.1002/jia2.25578. PubMed PMID:
32844591; PubMed Central PMCID:
PMC7448189.
Improving the HIV PrEP continuum of care using an intervention for healthcare providers: a stepped-wedge study protocol.
BMJ Open.
2020 Jul 14;10(7):e040734. doi: 10.1136/bmjopen-2020-040734. PubMed PMID:
32665393; PubMed Central PMCID:
PMC7454188.
What would you like to do?